5 Best Drug Stocks To Buy Now

4. Organon & Co. (NYSE:OGN)

Number of Hedge Fund Holders: 27

Organon & Co. (NYSE:OGN) is a New Jersey-based healthcare company that offers women’s health, cardiovascular, immunology, and pain management drugs to wholesalers and retailers, hospitals, government agencies, and managed health care providers. 

Goldman Sachs analyst Chris Shibutani on April 27 initiated coverage of Organon & Co. (NYSE:OGN) with a Buy rating and a $40 price target, implying 26% upside from present levels. The value currently attributed to Organon & Co. (NYSE:OGN)’s women’s health business does not fully appreciate its ability to position the fertility products portfolio to take advantage of the positive secular trends and feasible market dynamics, the analyst told investors in a research note. He sees growth higher than historical levels and consensus estimates.

Among the hedge funds tracked by Insider Monkey, 27 funds were long Organon & Co. (NYSE:OGN) at the end of March 2022, compared to 31 funds in the prior quarter. Cliff Asness’ AQR Capital Management is the largest shareholder of the company, with 3.12 million shares worth $109 million.